Health Condition 1: G890- Central pain syndrome
Conditions
Interventions
Intervention1: Pregabalin: PREGABALIN started at 150 mg/day in two divided doses and titrated in 1 week max upto 300 mg/day in two divided doses
Control Intervention1: Amitryptiline: AMITRYPTILINE st
Sponsors
AIIMS Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient of age > 18 years to be taken into the study. 2. Ischaemic, haemorhagic or cardioembolic all types of strokes are to be included. 3. Patients with intact sensorium to be included only. 4. Patients having score more than 5 on visual analogue scale to be included in the study. 5. Patients who are already on any other drugs for CPSP can be included in the study after providing a washout period of two weeks. 6. Only first episode stroke patients to be taken in the study. 7. Presenting in neurology OPD/IPD/Emergency of AIIMS Bhubaneswar. 8. Period of recruitment of patients presenting between July 2020 to May 2022.
Exclusion criteria
Exclusion criteria: 1. Patients with history of recurrent stroke to be excluded. 2. Venous strokes to be excluded 3. Patients with altered sensorium at the baseline to be excluded. 4. Other forms of post stroke pain like undefined complex regional pain syndrome, subluxation of shoulder to be excluded. 5. Patients with any comorbidities that limits the use of the drugs involved in the study to be excluded at baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| more than 50% reduction in visual analogue scale from the baseline to endpointTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the Barthel index score from baseline to endpoint. Modified Rankin scale (mRS) scale comparison from baseline to endpoint. Hospital anxiety and depression scale comparison from baseline to endpoint. Electrophysiological assessment at the baseline and endpoint. Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Camelia Porey
AIIMS Bhubaneswar
Outcome results
None listed